期刊文献+

大鼠胰腺癌和非癌胰腺组织中EZH_2和PTEN的表达及其意义 被引量:1

Expression and significance of EZH_2 and PTEN in pancreatic cancer and non-cancerous pancreatic tissues in rats
原文传递
导出
摘要 目的探讨大鼠胰腺癌和非癌胰腺组织中EZH2和PTEN的表达水平及其在胰腺癌发生中所起的作用。方法将二甲基苯荓蒽(DMBA)直接置入胰腺实质内制备胰腺癌模型(A,B组),B组成模1周后每周腹腔注射曲古霉素A(TSA)1μg,A,B组3~5个月内处死,对照组(C组)于第5个月处死;肉眼检查和镜下观察胰腺癌发生情况。EnVisionTM免疫组化法检测3组EZH2和PTEN的表达。结果(1)A组3~5个月癌发生率为48.7%(18/37),17例为胰腺导管腺癌,1例为纤维肉瘤;B组3~5个月癌发生率为33.3%(12/36),11例为胰腺导管腺癌,1例为纤维肉瘤;A组胰腺癌最大径均值大于B组(P〈0.05);C组胰腺和A,B,2组胰腺外主要脏器均未见明显病理改变。(2)A,B组胰腺导管腺癌EZH2表达阳性率明显高于相应非癌胰腺组织(P〈0.01);A组+B组胰腺导管癌PTEN表达阳性率明显低于A组+B组非癌胰腺组织(P〈0.05),但A组和B组胰腺导管癌PTEN表达阳性率与A组或B组非癌胰腺组织间差异无统计学意义(P〉0.05);EZH2阳性表达和/或PTEN阴性表达的非癌胰腺组织导管上皮均呈轻至重度不典型增生;胰腺导管癌中EZH2与PTEN表达呈明显不一致性(P=0.045);C组正常胰腺EZH2表达均阴性而PTEN表达均阳性。2例纤维肉瘤EZH2和PTEN表达均阴性。结论较大剂量DMBA置入胰实质内可获得较高胰腺癌发生率,TSA能抑制胰腺癌的发生和生长;EZH2基因的激活及PTEN基因的失活在大鼠胰腺癌发生中可能起关键作用。 Objective To study the expressive levels of EZH2 and PTEN in pancreatic cancer and non-cancerous tissue,and the effects on carcinogenesis of rat pancreas.Methods dimethylbenzathracene(DMBA) was directly implanted into the parenchyma of rat pancreas(group A,group B).The rats of group B were treated with 1 mL trichostatin A(TSA) solution(1μg/mL) intravenously per weer 1 week after the model were set up.The rats of group A,B were killed within 3-5 months and the rats in the control(C group) were executed at 5 months to observe the develope of pancreatic cancer by macrograph and microscopy,The EnVisionTM immunohistochemistry was used to assay the expression of EZH2 and PTEN in above pancreatic specimens.Results(1) The incidence of pancreatic cancer within 3-5 months in group A was 48.7%(18/37),including 17 cases of ductal adenocarcinoma and 1 case of fibrosarcoma.The incidence of pancreatic cancer in group B was 33.3%(12/36),including 11 cases of ductal adenocarcinoma and 1 cases of fibrosarcoma.The mean maximal diameter of mass was significantly higher in group A than that in group B(P 0.05).No pathological changes were found in pancreas of group C or other main organs of group A and group B.(2) the positive rxpression rates of EZH2 were significantly higher in ductal adenocarcinoma of group A + group B than those in non-cancerous pancreatic tissues(P 0.01).The positive expression rate of PTEN was significantly lower in ductal adenocarcinoma in group A + group B than that in non-cancerous pancreatic tissues(P 0.05).But no stastical difference was found among the positive rate of PTEN in ductal adenocarcinoma of group A or group B and in non-cancerous pancreatic tissues of group A or group B(P 0.05).The non-cancerous pancreatic tissues with positive expression of EZH2 and/or negative expression of PTEN showed mild to severe atypical hyperplasia of ductal epithelium.An inconsistency was found between the expression of EZH2 and PTEN in ductal adenocarcinoma(P =0.045).Pancreas of group C showed negative expression of EZH2 and positive expression of PTEN.Two cases of fibrosarcoma showed negative expression of EZH2 and PTEN.Conclusions By use of higher dose of DMBA directly implanted into the parenchyma of pancreas,high incidence of pancreatic cancer can be obtained.TSA could have an inhibitive effect on carcinogenesis and growth of pancratic cancer.The activation of EZH2 gene and inactivation of PTEN gene might have Key effects on pancreas carcinogenesis induced by DMBA in rat.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2010年第3期250-254,共5页 China Journal of General Surgery
关键词 胰腺肿瘤 模型 动物 果蝇zesle基因增强子2 PTEN抑癌基因 免疫组织化学 大鼠 Pancreatic Neoplasms Models Animal EZH2 PTEN Immunohistochemistry Rats
  • 相关文献

参考文献23

  • 1Varambally S, Dhanasekara SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer[J]. Nature, 2002,419(6907) :624 -629.
  • 2Brugant RJ, Cross NA, Eaton CL, et al. EZH2 promotes proliferation and invasiveness of prostate cancer cells [ J ]. Prostate,2007,67 (5) :547 - 556.
  • 3Ding L, Kleer CG. Enhancer of zeste 2 as a marker of preneoplastic progression in the breast [ J ] . Cancer Res, 2006, 66(19) :9352 -9355.
  • 4Mattioli E, Vogiatzi P, Sun A, et al. Immunohistochemical analysis of PRb2/p130, VEGF, EZH2, P53, P16 (INK4A) , P27(KIPI) , P21 (WAF1) , ki-67 expression patterns in gastric cancer [ J ] . J Cell Physiol, 2007 , 210(1) :183 -191.
  • 5Matsukawa Y, Semba S, Kato H, et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer[J]. Cancer Sci, 2006, 97(6) : 484 -491.
  • 6Collett K, Eide GE, Ames J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor proliferation and is a marker of aggressive breast cancer [J]. Clin Cancer Res, 2006,12(4) :1168-1174.
  • 7Bachmann IM, Halvorsen O J, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroup in cutaneous melanoma and cancers of the endometrium, prostate and breast [ J ]. J Clin Oncol, 2006,24(2) :268 -273.
  • 8Sudo J, Utsunomiya T, Mimori K, et al. Clincopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma [ J]. Br J Cancer, 2005,92 (9) : 1754-1758.
  • 9Cirpan T, Aygnl S, Terek MC, et al. MMAC tumor suppressor gene expression in ovarian endometriosis and ovarian adenocarcinoma[ J ]. Eur J Gynaecol Oncol, 2007,28 (4) : 278 -281.
  • 10Hwang PH, Kim SY, Lee JC, et al. PTEN/MMAC1 enhances the growth inhibition by anticancer drugs with down regulation of IGF-II expression in gastric cencer ceils [ J ] . Exp Mol Med, 2005, 37(5) :391 -385.

二级参考文献41

  • 1张建华,杨为民,周四维.PTEN基因转染对人膀胱癌细胞系BIU-87增殖和侵袭力的影响[J].中华实验外科杂志,2006,23(3):368-368. 被引量:7
  • 2崔平,普苹,赵晓霞,吴韬,杨世昆,胡筑培.胆系恶性肿瘤p16,PTEN和nm23基因的表达及其临床意义[J].中国普通外科杂志,2006,15(3):195-197. 被引量:4
  • 3Ohta M, Inoue H, Cotticelli MG, et al. The human FHIT gene, spanning the chromosome 3 p 14. 2 fragile site and renal carcinoma associated translocation breakpoint, is abnormal in digestive tract cancers [ J ]. Cell, 1996, 84 (4) :587 -597.
  • 4Steck PA, Pershouse MA, Jasser SA, et al. Identification of candidate tumour suppressor gene, MMAC 1, at chromosome 10q23. 3 that is mutated in multiple advanced cancer [ J ].Nat Genet, 1997, 15(4) :356 -362.
  • 5Masaharu K, Kazuo Y, Koichirou K, et al. Expression of FHIT, Mlh 1 , and p53 protein in human gallbladder carcinoma [J]. Cancer Letters, 2003, 199(2) :131 - 138.
  • 6Torres J, Navarro S, Roglá I, et al. Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues [ J] . Eur J Cancer, 2001 , 37 (1) :114 -121.
  • 7Wistuba Ⅱ , Ashfaq R , Maitra A , et a l. Fragile Histidine Triad Gene Abnormalities in the Pathogenesis of Gallbladder Carcinoma [ J ]. Am J Pathol, 2002, 160 ( 6 ): 2073 -2079.
  • 8Mady HH, Melhem MF. FHIT protein expression and its relation to apoptosis, tumor histologic grade and prognosis in colorectal adenocarcinoma: an immunohistochemical and image analysis study [ J]. Clin Exp Metastasis, 2002,19(4) :351 -358.
  • 9Myers MP , Stolarov P , Eng C. PTEN , the tumor suppressor form human 10q23, is a dual specificity phosphatase [ J ].Proc Natl Acad Sci USA, 1997, 94 ( 17 ) : 9052 -9057.
  • 10Li J,Yen C,Liaw D,et al.PTEN,a putative protein tyrosine phosphatase gene mutated in human brain,breast,and prostate cancer[J].Science,1997,275:1943-1947.

共引文献94

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部